Mangoceuticals, Inc. (MGRX)
Mangoceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Mangoceuticals, Inc. (MGRX) is a Medical - Healthcare Information Services company based in US with a market capitalization of $4.8M. Revenue declined 26.0% year-over-year and free cash flow was negative at -$5.9M. This page tracks MGRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 3 employees · IPO Mar 21, 2023
Valuation
Valuation & price
$0.45as of May 23, 2026· -83.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.32
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$4.8M
Market cap
-26.0%
Revenue growth (YoY)
54.9%
Gross margin
-$5.9M
Free cash flow (USD)
-$1.2M
Net debt
Net cash position
408.9%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2021 → 2025
Free cash flow by year
2021 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 19, 2026 (EPS $-0.22)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Mangoceuticals, Inc.'s market cap?
Mangoceuticals, Inc. (MGRX) has a market capitalization of $4.8M.
What is MGRX's P/E ratio?
A meaningful P/E ratio is not available for MGRX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is MGRX's price-to-book (P/B) ratio?
MGRX trades at 0.32 times book value per share.
When did Mangoceuticals, Inc. last report earnings?
MGRX last reported earnings on May 19, 2026; the next date is not yet scheduled.
Are insiders buying MGRX stock?
SEC Form 4 filings show no open-market insider buys at Mangoceuticals, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Medical - Healthcare Information Services
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.